L-NIL HCl | CAS#159190-45-1| iNOS inhibitor

MedKoo Cat#: 597660 | Name: L-NIL HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-NIL HCl is a relatively selective inhibitor of iNOS. It exhibits IC50 values of 0.4-3.3 µM for iNOS as opposed to 8-38 and 17-92 µM for eNOS and nNOS, respectively. L-NIL effectively inhibits iNOS both in vitro and in vivo.4,5,3 L-NIL has been used to demonstrate a critical role for iNOS in the immune response to infection by the protozoan L. major.

Chemical Structure

L-NIL HCl

CAS#159190-45-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 597660

Name: L-NIL HCl

CAS#: 159190-45-1 (HCl)

Chemical Formula: C8H19Cl2N3O2

Exact Mass:

Molecular Weight: 260.16

Elemental Analysis: C, 36.93; H, 7.36; Cl, 27.25; N, 16.15; O, 12.30

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 350.00	2 Weeks
100mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

N-Iminoethyl-L-lysine dihydrochloride; L-NIL HCl;

IUPAC/Chemical Name

(2-iminoethyl)-L-lysine dihydrochloride

InChi Key

FHJAAUCMOJCQKP-KLXURFKVSA-N

InChi Code

InChI=1S/C8H17N3O2.2ClH/c9-4-2-1-3-7(8(12)13)11-6-5-10;;/h5,7,10-11H,1-4,6,9H2,(H,12,13);2*1H/t7-;;/m0../s1

SMILES Code

NCCCC[C@@H](C(O)=O)NCC=N.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L-NIL dihydrochloride is an inducible NO synthase inhibitor, with an IC50 of 3.3 μM for miNOS.

In vitro activity:

Further, elevated O-GlcNAc acted on Il-6 expression through the iNOS pathway, as iNOS inhibitior L-NIL raised wildtype Il-6 expression similar to OGA deficient cells but had no further effect on the hyper-O-GlcNAcylated cells. Reference: Front Immunol. 2022 Apr 1;13:802336. https://pubmed.ncbi.nlm.nih.gov/35432339/

In vivo activity:

Mice were divided into normal control (NC), sham, sepsis saline (SS), and sepsis Arg (SA) groups. In order to investigate the role of NO, L-N6-(1-iminoethyl)-lysine hydrochloride (L-NIL), an inducible NO synthase inhibitor, was administered to the sepsis groups. Changes in plasma NO and renal NLRP3 inflammasome-related protein expression were abrogated when L-NIL was given to the Arg sepsis groups. Arg plus L-NIL administration also attenuated kidney injury after CLP. Reference: Mediators Inflamm. 2020 May 11;2020:3201635. https://pubmed.ncbi.nlm.nih.gov/32454788/

	Solvent	mg/mL	mM
Solubility
	DMF	15.0	57.66
	DMSO	15.0	57.66
	Ethanol	1.0	3.84
	PBS	30.0	115.31
	Water	30.0	192.19

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 260.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Abramowitz LK, Hanover JA. Chronically Elevated O-GlcNAcylation Limits Nitric Oxide Production and Deregulates Specific Pro-Inflammatory Cytokines. Front Immunol. 2022 Apr 1;13:802336. doi: 10.3389/fimmu.2022.802336. PMID: 35432339; PMCID: PMC9010940. 2. Kang JK, Hyun CG. 4-Hydroxy-7-Methoxycoumarin Inhibits Inflammation in LPS-activated RAW264.7 Macrophages by Suppressing NF-κB and MAPK Activation. Molecules. 2020 Sep 26;25(19):4424. doi: 10.3390/molecules25194424. PMID: 32993156; PMCID: PMC7583757. 3. Tanuseputero SA, Lin MT, Yeh SL, Yeh CL. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635. doi: 10.1155/2020/3201635. PMID: 32454788; PMCID: PMC7238342. 4. Pasten C, Alvarado C, Rocco J, Contreras L, Aracena P, Liberona J, Suazo C, Michea L, Irarrázabal CE. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634. doi: 10.1152/ajprenal.00398.2018. Epub 2018 Dec 5. PMID: 30516425.

In vitro protocol:

In vivo protocol:

1. Tanuseputero SA, Lin MT, Yeh SL, Yeh CL. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635. doi: 10.1155/2020/3201635. PMID: 32454788; PMCID: PMC7238342. 2. Pasten C, Alvarado C, Rocco J, Contreras L, Aracena P, Liberona J, Suazo C, Michea L, Irarrázabal CE. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634. doi: 10.1152/ajprenal.00398.2018. Epub 2018 Dec 5. PMID: 30516425.

1: Lu G, Zhang R, Geng S, Peng L, Jayaraman P, Chen C, Xu F, Yang J, Li Q, Zheng H, Shen K, Wang J, Liu X, Wang W, Zheng Z, Qi CF, Si C, He JC, Liu K, Lira SA, Sikora AG, Li L, Xiong H. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nat Commun. 2015 Mar 27;6:6676. doi: 10.1038/ncomms7676. PubMed PMID: 25813085; PubMed Central PMCID: PMC4389243. 2: Tong J, Wang Y, Chang B, Zhang D, Liu P, Wang B. Activation of RhoA in alcohol-induced intestinal barrier dysfunction. Inflammation. 2013 Jun;36(3):750-8. doi: 10.1007/s10753-013-9601-7. PubMed PMID: 23361851. 3: Sinha BK, Kumar A, Bhattacharjee S, Espey MG, Mason RP. Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells. J Pharmacol Exp Ther. 2013 Dec;347(3):607-14. doi: 10.1124/jpet.113.207928. Epub 2013 Sep 18. PubMed PMID: 24049059; PubMed Central PMCID: PMC3836306. 4: Lendeckel U, Wolke C, Bernstein HG, Keilhoff G. Effects of nitric oxide synthase deficiency on a disintegrin and metalloproteinase domain-containing protein 12 expression in mouse brain samples. Mol Med Rep. 2015 Aug;12(2):2253-62. doi: 10.3892/mmr.2015.3643. Epub 2015 Apr 17. PubMed PMID: 25892053. 5: Morgese MG, Colaianna M, Mhillaj E, Zotti M, Schiavone S, D'Antonio P, Harkin A, Gigliucci V, Campolongo P, Trezza V, De Stradis A, Tucci P, Cuomo V, Trabace L. Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1. Front Neurosci. 2015 Nov 5;9:428. doi: 10.3389/fnins.2015.00428. eCollection 2015. PubMed PMID: 26594145; PubMed Central PMCID: PMC4633524. 6: Gupta I, Ganguly S, Rozanas CR, Stuehr DJ, Panda K. Ascorbate attenuates pulmonary emphysema by inhibiting tobacco smoke and Rtp801-triggered lung protein modification and proteolysis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4208-17. doi: 10.1073/pnas.1600056113. Epub 2016 Jul 5. PubMed PMID: 27382160; PubMed Central PMCID: PMC4961122. 7: Capulli M, Olstad OK, Onnerfjord P, Tillgren V, Muraca M, Gautvik KM, Heinegård D, Rucci N, Teti A. The C-terminal domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss. J Bone Miner Res. 2014 Aug;29(8):1833-46. doi: 10.1002/jbmr.2206. PubMed PMID: 24616121. 8: Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15;16(6):1834-44. doi: 10.1158/1078-0432.CCR-09-3123. Epub 2010 Mar 9. PubMed PMID: 20215556; PubMed Central PMCID: PMC2858983. 9: Remizova MI, Gerbut KA, Kochetygov NI. Effect of selective inhibitors of nitric oxide synthesis on the course of experimental hemorrhagic shock. Bull Exp Biol Med. 2010 Oct;149(5):571-4. PubMed PMID: 21165389. 10: Jianjun Yang, Zhang R, Lu G, Shen Y, Peng L, Zhu C, Cui M, Wang W, Arnaboldi P, Tang M, Gupta M, Qi CF, Jayaraman P, Zhu H, Jiang B, Chen SH, He JC, Ting AT, Zhou MM, Kuchroo VK, Morse HC 3rd, Ozato K, Sikora AG, Xiong H. T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation. J Exp Med. 2013 Jul 1;210(7):1447-62. PubMed PMID: 23797094; PubMed Central PMCID: PMC3698516. 11: Soliman H, Craig GP, Nagareddy P, Yuen VG, Lin G, Kumar U, McNeill JH, Macleod KM. Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res. 2008 Jul 15;79(2):322-30. doi: 10.1093/cvr/cvn095. Epub 2008 Apr 14. PubMed PMID: 18411229. 12: Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res. 2005 Mar 1;65(4):803-12. PubMed PMID: 15721860. 13: Franco L, Doria D. Nitric oxide enhances prostaglandin production in ethanol-induced gastric mucosal injury in rats. Eur J Pharmacol. 1998 May 8;348(2-3):247-56. PubMed PMID: 9652340. 14: Li DB, Fu ZX, Ruan SQ, Hu SJ, Li X. Acetylsalicylic acid regulates overexpressed small GTPase RhoA in vascular smooth muscle cells through prevention of new synthesis and enhancement of protein degradation. Biosci Rep. 2012 Apr 1;32(2):153-60. doi: 10.1042/BSR20110050. PubMed PMID: 21756248. 15: Nagareddy PR, McNeill JH, MacLeod KM. Chronic inhibition of inducible nitric oxide synthase ameliorates cardiovascular abnormalities in streptozotocin diabetic rats. Eur J Pharmacol. 2009 Jun 2;611(1-3):53-9. doi: 10.1016/j.ejphar.2009.03.061. Epub 2009 Apr 1. PubMed PMID: 19344709. 16: Correia PN, Carpenter GH, Paterson KL, Proctor GB. Inducible nitric oxide synthase increases secretion from inflamed salivary glands. Rheumatology (Oxford). 2010 Jan;49(1):48-56. doi: 10.1093/rheumatology/kep313. Epub 2009 Nov 20. PubMed PMID: 19933597; PubMed Central PMCID: PMC2789584. 17: Land SC, Rae C. iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core. Am J Physiol Cell Physiol. 2005 Oct;289(4):C918-33. Epub 2005 May 18. PubMed PMID: 15901597. 18: Resta TC, O'Donaughy TL, Earley S, Chicoine LG, Walker BR. Unaltered vasoconstrictor responsiveness after iNOS inhibition in lungs from chronically hypoxic rats. Am J Physiol. 1999 Jan;276(1 Pt 1):L122-30. PubMed PMID: 9887064. 19: Bateman RM, Sharpe MD, Goldman D, Lidington D, Ellis CG. Inhibiting nitric oxide overproduction during hypotensive sepsis increases local oxygen consumption in rat skeletal muscle. Crit Care Med. 2008 Jan;36(1):225-31. PubMed PMID: 18090362. 20: Jüttner S, Bernhagen J, Metz CN, Röllinghoff M, Bucala R, Gessner A. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol. 1998 Sep 1;161(5):2383-90. PubMed PMID: 9725234.